EPISODE · May 7, 2026 · 1 MIN
EyePoint's DURAVYU: Revolutionizing Retinal Care
from The Daily News Now! Business
EyePoint Pharmaceuticals Q1 2026 earnings highlight DURAVYUs potential in wet AMD and DME, with Phase III trials and DME trials progressing. Positive safety data and cash reserves support their push into a $15 billion market. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/e66e385178d3a0b3
NOW PLAYING
EyePoint's DURAVYU: Revolutionizing Retinal Care
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m